View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
WEDNESDAY, Dec. 18, 2013 (HealthDay News) -- A new inhaled drug to treat chronic obstructive pulmonary disease (COPD) has been approved by the U.S. Food and Drug Administration.
GlaxoSmithKline's Anoro Ellipta is meant to be used once a day for long-term maintenance of airflow in patients with COPD. Anoro Ellipta combines umeclidinium, an inhaled anticholinergic, and vilanterol, a long-acting beta2-adrenergic agonist.
The FDA approval is based on findings from more than 2,400 people with COPD. The results showed that those who took the drug had greater improvements in lung function than those who took a placebo. The most common side effects reported by patients who took Anoro Ellipta included pharyngitis, sinusitis, lower respiratory tract infection, constipation, diarrhea, pain in extremities, muscle spasms, neck pain, and chest pain.
Serious side effects that can be caused by the drug include paradoxical bronchospasm, cardiovascular effects, acute narrow-angle glaucoma, and worsening of urinary retention.
Anoro Ellipta is not approved for asthma treatment and should not be used as a rescue treatment for acute bronchospasm, the FDA said. The drug carries a boxed warning that the class of drugs that vilanterol belongs to increases the risk of asthma-related death.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top